Follicular lymphoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:
{{CMG}}; {{AE}} {{AS}}
{{CMG}}; {{AE}} {{AS}}
==Overview==
==Overview==
Prognosis of follicular lymphoma is generally poor. The [[median]] survival is around 10 years.
Prognosis of follicular lymphoma is generally poor and the 5 year survival rate of patients is approximately 72-77%.
==Prognosis==
==Prognosis==
*Follicular lymphoma is regarded as incurable (although allogenic [[stem cell transplantation]] may be curative, the mortality from the procedure is too high to be a first line option). The [[median]] survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment. The overall survival rate at 5 years is 72-77%.<ref>{{EMedicine|article|203268|Lymphoma, Follicular}}</ref>
*Follicular lymphoma is regarded as incurable (although allogenic [[stem cell transplantation]] may be curative, the mortality from the procedure is too high to be a first line option). The [[median]] survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment. The overall survival rate at 5 years is 72-77%<ref>{{EMedicine|article|203268|Lymphoma, Follicular}}</ref>.
*Follicular lymphoma is graded according to the proportion of large cells (centroblasts). Studies suggest this histologic grading predicts clinical outcome, with more large cells behaving more aggressively and having a higher likelihood of transformation to diffuse large cell lymphoma. When any area of diffuse large-B-cell lymphoma is present in a follicular lymphoma the disease should be reported as diffuse large B-cell lymphoma.<ref name="seer">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>.  
*Follicular lymphoma is graded according to the proportion of large cells (centroblasts). Studies suggest this histologic grading predicts clinical outcome, with more large cells behaving more aggressively and having a higher likelihood of transformation to diffuse large cell lymphoma. When any area of diffuse large-B-cell lymphoma is present in a follicular lymphoma the disease should be reported as diffuse large B-cell lymphoma<ref name="seer">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>.  
*There was no difference in survival outcomes between patients with Grade 3A and 3B follicular lymphoma, whereas patients with FL3 with more than 50% diffuse component have an inferior survival similar to the survival of those with diffuse large cell lymphoma.  
*There was no difference in survival outcomes between patients with Grade 3A and 3B follicular lymphoma, whereas patients with FL3 with more than 50% diffuse component have an inferior survival similar to the survival of those with diffuse large cell lymphoma.  
*FL3B with cytogenetic abnormalities of BCL6 (at 3q27) are thought to be genetically more akin to germinal center type diffuse large B-cell lymphoma than FL1-3A, and is associated with a more aggressive clinical course.
*FL3B with cytogenetic abnormalities of ''BCL6'' (at 3q27) are thought to be genetically more akin to germinal center type diffuse large B-cell lymphoma than FL1-3A, and is associated with a more aggressive clinical course.
*Patients with FL3B with BCL2 [[translocation]] appear to have a clinical course similar to patients with FL1-3A. Since FL3B is rare, the clinical behavior of FL3 in most studies is based mainly on FL3A cases.  
*Patients with FL3B with ''BCL2'' [[translocation]] appear to have a clinical course similar to patients with FL1-3A. Since FL3B is rare, the clinical behavior of FL3 in most studies is based mainly on FL3A cases.  


==References==
==References==

Revision as of 19:11, 28 August 2015

Follicular lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Follicular lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT scan

MRI

Echocardiography or Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Follicular lymphoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Follicular lymphoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Follicular lymphoma natural history, complications and prognosis

CDC on Follicular lymphoma natural history, complications and prognosis

Follicular lymphoma natural history, complications and prognosis in the news

Blogs on Follicular lymphoma natural history, complications and prognosis

Directions to Hospitals Treating Follicular lymphoma

Risk calculators and risk factors for Follicular lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Prognosis of follicular lymphoma is generally poor and the 5 year survival rate of patients is approximately 72-77%.

Prognosis

  • Follicular lymphoma is regarded as incurable (although allogenic stem cell transplantation may be curative, the mortality from the procedure is too high to be a first line option). The median survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment. The overall survival rate at 5 years is 72-77%[1].
  • Follicular lymphoma is graded according to the proportion of large cells (centroblasts). Studies suggest this histologic grading predicts clinical outcome, with more large cells behaving more aggressively and having a higher likelihood of transformation to diffuse large cell lymphoma. When any area of diffuse large-B-cell lymphoma is present in a follicular lymphoma the disease should be reported as diffuse large B-cell lymphoma[2].
  • There was no difference in survival outcomes between patients with Grade 3A and 3B follicular lymphoma, whereas patients with FL3 with more than 50% diffuse component have an inferior survival similar to the survival of those with diffuse large cell lymphoma.
  • FL3B with cytogenetic abnormalities of BCL6 (at 3q27) are thought to be genetically more akin to germinal center type diffuse large B-cell lymphoma than FL1-3A, and is associated with a more aggressive clinical course.
  • Patients with FL3B with BCL2 translocation appear to have a clinical course similar to patients with FL1-3A. Since FL3B is rare, the clinical behavior of FL3 in most studies is based mainly on FL3A cases.

References

  1. Lymphoma, Follicular at eMedicine
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov